T cells in Lupus
T cells in Lupus
批准号:
10308697
负责人:
George C Tsokos
金额:
$43.75万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-12-01 至 2024-11-30
关键词:
AddressAmericanAutoimmunityBiological MarkersCD8-Positive T-LymphocytesCD8B1 geneCell physiologyCellsClinical ResearchConsumptionDefectDevelopmentDiagnosisDiseaseDrug Delivery SystemsDrug TargetingGene ExpressionGenesGenetic TranscriptionGlycolysisHumanImmuneImmune ToleranceImmune responseImmunologistImmunosuppressive AgentsInfectionLeadLinkLupusMembraneMetabolicMetabolismMolecularMorbidity - disease rateMusNatural Killer CellsNicotinamide adenine dinucleotideOrganOrganellesOxidative PhosphorylationPathologyPatientsPerformancePilot ProjectsPredispositionProspective StudiesResearchRoleSurfaceSymptomsSystemic Lupus ErythematosusT-LymphocyteT-Lymphocyte SubsetsTestingWomanWorkcohortcytotoxiccytotoxicitydesignexperimental studyimprovedinfection ratelupus prone micemortalitynoveloverexpressionprospectiveresponsetargeted biomarkertargeted deliverytranslational scientist
中文摘要
导致大鼠耐受性和器官病理破坏的多种机制
系统性红斑狼疮(SLE)患者对两位基础免疫学家都提出了挑战
和翻译研究人员。感染仍然是发病和死亡的主要原因之一
尽管我们显著提高了诊断和治疗SLE的能力,但SLE患者的死亡率仍然很高
及早有效地治疗感染。
对SLE患者T细胞表达基因的研究发现CD38与SLE相关
更严重的疾病和广泛的基因异常表达。CD8+CD38+T细胞
在系统性红斑狼疮患者中发现扩张,并与感染增加密切相关
费率。CD8+CD38+细胞显示细胞毒活性受损,烟酰胺含量减少
腺二核苷酸(NAD+),减少糖酵解和氧化磷酸化,并
负责细胞毒性细胞功能的分子表达减少。
此外,抑制CD38似乎可以恢复部分细胞毒细胞功能。
指导这项研究的假设是:CD38在卵巢癌中的表达增加
SLE患者和狼疮易感小鼠CD8+细胞对其细胞毒活性和
容易感染,并促进自身免疫力。利用人类细胞进行的三组实验
并将进行新的小鼠来验证这一假设。第一个将决定CD38如何
表达限制了CD8细胞的细胞毒作用。第二项研究将探讨如何加强
系统性红斑狼疮CD8+细胞的细胞毒作用,包括靶向给药给T细胞。鉴于,
在第三项研究中,我们将进行一项试验性前瞻性研究,以确定CD38表达的价值
在确定系统性红斑狼疮患者容易感染方面。
系统性红斑狼疮患者外周血中CD8+CD38+T细胞亚群的鉴定及意义
CD38在限制其细胞毒活性以及设计新的小鼠方面代表了新的
狼疮领域的概念。寻找恢复其细胞毒活性的方法和
将它们定义为SLE患者易感染的生物标志物的临床研究代表了
这一系列研究的翻译价值。
英文摘要
The multitude of mechanisms that lead to general break of tolerance and organ pathology in
patients with systemic lupus erythematosus (SLE) have challenged both basic immunologists
and translational researchers. Infections remain one of the main causes of morbidity and
mortality among patients with SLE despite our significantly improved ability to diagnose and
treat infections early and efficiently.
Search for genes expressed in T cells from patients with SLE revealed CD38 to be associated
with more severe disease and extensive aberrant gene expression. CD8+CD38+ T cells were
found expanded in patients with SLE and to be strongly associated with increased infection
rates. CD8+CD38+ cells display compromised cytotoxic activity, less amounts of nicotinamide
adenine dinucleotide (NAD+), decreased glycolysis and oxidative phosphorylation and
decreased expression of molecules responsible for the performance of cytotoxic cell function.
In addition, inhibition of CD38 appeared to restore aspects of cytotoxic cell function.
The hypothesis which will guide the proposed studies is: increased expression of CD38 on
CD8+ cells in patients with SLE and lupus-prone mice compromises their cytotoxic activity and
predisposes to infections and drives autoimmunity. Three sets of experiments using human cells
and novel mice will be conducted to test the hypothesis. The first will determine how CD38
expression limits cytotoxicity in CD8 cells. The second will explore approaches to enhance
cytotoxic responses of SLE CD8+ cells including targeted delivery of drugs to T cells. Whereas,
in the third we will conduct a pilot prospective study to determine the value of CD38 expression
in identifying patients with SLE prone to infections.
The identification of the CD8+CD38+ T cell subset to be expanded in SLE patients and role of
CD38 in limiting their cytotoxic activity along with the design of new mice represent novel
concepts in the field of lupus. The search for approaches to restore their cytotoxic activity and
the clinical study to define them as a biomarker for SLE patients prone to infections represent
the translational value of this line of research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T cells in Lupus
-
批准号:10533282
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2019
-
负责人:George C Tsokos
-
依托单位:
T cells in Lupus
-
批准号:10063477
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2019
-
负责人:George C Tsokos
-
依托单位:
Phosphatases in Systemic Autoimmunity
-
批准号:10468134
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2018
-
负责人:George C Tsokos
-
依托单位:
Phosphatases in Systemic Autoimmunity
-
批准号:10000837
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2018
-
负责人:George C Tsokos
-
依托单位:
Phosphatases in Systemic Autoimmunity
-
批准号:10242137
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2018
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:9247888
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:8640886
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:8480535
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:9040093
-
项目类别:
-
资助金额:$35.97万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8453448
-
项目类别:
-
资助金额:$40.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8653524
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:7791807
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8066298
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10620721
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10295607
-
项目类别:
-
资助金额:$52.36万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8259759
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10424576
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7664206
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2009
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7800479
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2009
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7484755
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2008
-
负责人:George C Tsokos
-
依托单位:
海外基金